186 related articles for article (PubMed ID: 27209355)
1. ATRX driver mutation in a composite malignant pheochromocytoma.
Comino-Méndez I; Tejera ÁM; Currás-Freixes M; Remacha L; Gonzalvo P; Tonda R; Letón R; Blasco MA; Robledo M; Cascón A
Cancer Genet; 2016 Jun; 209(6):272-7. PubMed ID: 27209355
[TBL] [Abstract][Full Text] [Related]
2. Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas.
Fishbein L; Khare S; Wubbenhorst B; DeSloover D; D'Andrea K; Merrill S; Cho NW; Greenberg RA; Else T; Montone K; LiVolsi V; Fraker D; Daber R; Cohen DL; Nathanson KL
Nat Commun; 2015 Jan; 6():6140. PubMed ID: 25608029
[TBL] [Abstract][Full Text] [Related]
3. The genomic landscape of phaeochromocytoma.
Flynn A; Benn D; Clifton-Bligh R; Robinson B; Trainer AH; James P; Hogg A; Waldeck K; George J; Li J; Fox SB; Gill AJ; McArthur G; Hicks RJ; Tothill RW
J Pathol; 2015 May; 236(1):78-89. PubMed ID: 25545346
[TBL] [Abstract][Full Text] [Related]
4. Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis.
Comino-Méndez I; de Cubas AA; Bernal C; Álvarez-Escolá C; Sánchez-Malo C; Ramírez-Tortosa CL; Pedrinaci S; Rapizzi E; Ercolino T; Bernini G; Bacca A; Letón R; Pita G; Alonso MR; Leandro-García LJ; Gómez-Graña A; Inglada-Pérez L; Mancikova V; Rodríguez-Antona C; Mannelli M; Robledo M; Cascón A
Hum Mol Genet; 2013 Jun; 22(11):2169-76. PubMed ID: 23418310
[TBL] [Abstract][Full Text] [Related]
5. Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas.
Welander J; Söderkvist P; Gimm O
Endocr Relat Cancer; 2011 Dec; 18(6):R253-76. PubMed ID: 22041710
[TBL] [Abstract][Full Text] [Related]
6. Somatic mutations in H-RAS in sporadic pheochromocytoma and paraganglioma identified by exome sequencing.
Crona J; Delgado Verdugo A; Maharjan R; Stålberg P; Granberg D; Hellman P; Björklund P
J Clin Endocrinol Metab; 2013 Jul; 98(7):E1266-71. PubMed ID: 23640968
[TBL] [Abstract][Full Text] [Related]
7. Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas.
Castro-Vega LJ; Buffet A; De Cubas AA; Cascón A; Menara M; Khalifa E; Amar L; Azriel S; Bourdeau I; Chabre O; Currás-Freixes M; Franco-Vidal V; Guillaud-Bataille M; Simian C; Morin A; Letón R; Gómez-Graña A; Pollard PJ; Rustin P; Robledo M; Favier J; Gimenez-Roqueplo AP
Hum Mol Genet; 2014 May; 23(9):2440-6. PubMed ID: 24334767
[TBL] [Abstract][Full Text] [Related]
8. Whole-exome sequencing defines the mutational landscape of pheochromocytoma and identifies KMT2D as a recurrently mutated gene.
Juhlin CC; Stenman A; Haglund F; Clark VE; Brown TC; Baranoski J; Bilguvar K; Goh G; Welander J; Svahn F; Rubinstein JC; Caramuta S; Yasuno K; Günel M; Bäckdahl M; Gimm O; Söderkvist P; Prasad ML; Korah R; Lifton RP; Carling T
Genes Chromosomes Cancer; 2015 Sep; 54(9):542-54. PubMed ID: 26032282
[TBL] [Abstract][Full Text] [Related]
9. H-RAS mutations are restricted to sporadic pheochromocytomas lacking specific clinical or pathological features: data from a multi-institutional series.
Oudijk L; de Krijger RR; Rapa I; Beuschlein F; de Cubas AA; Dei Tos AP; Dinjens WN; Korpershoek E; Mancikova V; Mannelli M; Papotti M; Vatrano S; Robledo M; Volante M
J Clin Endocrinol Metab; 2014 Jul; 99(7):E1376-80. PubMed ID: 24684458
[TBL] [Abstract][Full Text] [Related]
10. Recommendations for somatic and germline genetic testing of single pheochromocytoma and paraganglioma based on findings from a series of 329 patients.
Currás-Freixes M; Inglada-Pérez L; Mancikova V; Montero-Conde C; Letón R; Comino-Méndez I; Apellániz-Ruiz M; Sánchez-Barroso L; Aguirre Sánchez-Covisa M; Alcázar V; Aller J; Álvarez-Escolá C; Andía-Melero VM; Azriel-Mira S; Calatayud-Gutiérrez M; Díaz JÁ; Díez-Hernández A; Lamas-Oliveira C; Marazuela M; Matias-Guiu X; Meoro-Avilés A; Patiño-García A; Pedrinaci S; Riesco-Eizaguirre G; Sábado-Álvarez C; Sáez-Villaverde R; Sainz de Los Terreros A; Sanz Guadarrama Ó; Sastre-Marcos J; Scolá-Yurrita B; Segura-Huerta Á; Serrano-Corredor Mde L; Villar-Vicente MR; Rodríguez-Antona C; Korpershoek E; Cascón A; Robledo M
J Med Genet; 2015 Oct; 52(10):647-56. PubMed ID: 26269449
[TBL] [Abstract][Full Text] [Related]
11. Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas.
Castro-Vega LJ; Letouzé E; Burnichon N; Buffet A; Disderot PH; Khalifa E; Loriot C; Elarouci N; Morin A; Menara M; Lepoutre-Lussey C; Badoual C; Sibony M; Dousset B; Libé R; Zinzindohoue F; Plouin PF; Bertherat J; Amar L; de Reyniès A; Favier J; Gimenez-Roqueplo AP
Nat Commun; 2015 Jan; 6():6044. PubMed ID: 25625332
[TBL] [Abstract][Full Text] [Related]
12. Candidate gene mutation analysis in bilateral adrenal pheochromocytoma and sympathetic paraganglioma.
Korpershoek E; Petri BJ; van Nederveen FH; Dinjens WN; Verhofstad AA; de Herder WW; Schmid S; Perren A; Komminoth P; de Krijger RR
Endocr Relat Cancer; 2007 Jun; 14(2):453-62. PubMed ID: 17639058
[TBL] [Abstract][Full Text] [Related]
13. Exome Sequencing of Uterine Leiomyosarcomas Identifies Frequent Mutations in TP53, ATRX, and MED12.
Mäkinen N; Aavikko M; Heikkinen T; Taipale M; Taipale J; Koivisto-Korander R; Bützow R; Vahteristo P
PLoS Genet; 2016 Feb; 12(2):e1005850. PubMed ID: 26891131
[TBL] [Abstract][Full Text] [Related]
14. Malignant pheochromocytomas/paragangliomas harbor mutations in transport and cell adhesion genes.
Wilzén A; Rehammar A; Muth A; Nilsson O; Tešan Tomić T; Wängberg B; Kristiansson E; Abel F
Int J Cancer; 2016 May; 138(9):2201-11. PubMed ID: 26650627
[TBL] [Abstract][Full Text] [Related]
15. Integrative analysis of miRNA and mRNA expression profiles in pheochromocytoma and paraganglioma identifies genotype-specific markers and potentially regulated pathways.
de Cubas AA; Leandro-García LJ; Schiavi F; Mancikova V; Comino-Méndez I; Inglada-Pérez L; Perez-Martinez M; Ibarz N; Ximénez-Embún P; López-Jiménez E; Maliszewska A; Letón R; Gómez Graña A; Bernal C; Alvarez-Escolá C; Rodríguez-Antona C; Opocher G; Muñoz J; Megias D; Cascón A; Robledo M
Endocr Relat Cancer; 2013 Aug; 20(4):477-93. PubMed ID: 23660872
[TBL] [Abstract][Full Text] [Related]
16. An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes.
Gimenez-Roqueplo AP; Dahia PL; Robledo M
Horm Metab Res; 2012 May; 44(5):328-33. PubMed ID: 22328163
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma.
Fishbein L; Leshchiner I; Walter V; Danilova L; Robertson AG; Johnson AR; Lichtenberg TM; Murray BA; Ghayee HK; Else T; Ling S; Jefferys SR; de Cubas AA; Wenz B; Korpershoek E; Amelio AL; Makowski L; Rathmell WK; Gimenez-Roqueplo AP; Giordano TJ; Asa SL; Tischler AS; ; Pacak K; Nathanson KL; Wilkerson MD
Cancer Cell; 2017 Feb; 31(2):181-193. PubMed ID: 28162975
[TBL] [Abstract][Full Text] [Related]
18. Whole exome sequencing is an efficient and sensitive method for detection of germline mutations in patients with phaeochromcytomas and paragangliomas.
McInerney-Leo AM; Marshall MS; Gardiner B; Benn DE; McFarlane J; Robinson BG; Brown MA; Leo PJ; Clifton-Bligh RJ; Duncan EL
Clin Endocrinol (Oxf); 2014 Jan; 80(1):25-33. PubMed ID: 24102379
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours.
Tsang VH; Dwight T; Benn DE; Meyer-Rochow GY; Gill AJ; Sywak M; Sidhu S; Veivers D; Sue CM; Robinson BG; Clifton-Bligh RJ; Parker NR
Endocr Relat Cancer; 2014 Jun; 21(3):415-26. PubMed ID: 24623741
[TBL] [Abstract][Full Text] [Related]
20. Molecular evaluation of a sporadic paraganglioma with concurrent IDH1 and ATRX mutations.
Zhang J; Jiang J; Luo Y; Li X; Lu Z; Liu Y; Huang J; Hou Y; Pang Y; Sun MYF; Wang TS; Evans DB; Pacak K; Zhuang Z; Gao X
Endocrine; 2018 Aug; 61(2):216-223. PubMed ID: 29846902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
